Hong Kong stock market active | CXO concept stocks rebounded in early trading, overseas loosening is expected to drive investment and financing to pick up, and there are frequent policies supporting innovative drugs.

CXO Concept Stocks rebounded in early trading, and as of the time of publication, Joinn Laboratories (06127) rose 10.73%, to HKD 7.33; Genscript Bio (01548) rose 5.19%, to HKD 9.53; Pharmaron (03759) rose 5.13%, to HKD 8.6; Tigermed (03347) rose 4.56%, to HKD 28.65.

Zhitong FinanceJul 10 22:40 ET

Tigermed (03347.HK) encountered shareholding reduction from Canada Pension Plan Investment Board for 0.7371 million shares.

According to the latest equity disclosure information from the HKEX, on July 5, 2024, Tigermed (03347.HK) was reduced by Canada Pension Plan Investment Board by 0.7371 million shares at an average price of HKD 28.2456 per share, involving about HKD 20.82 million. After the reduction, Canada Pension Plan Investment Board's latest shareholding has decreased from 5.31% to 4.71%, with a current total shareholding of 5.7989 million shares.

Gelonghui FinanceJul 10 18:31 ET

Statistics on abnormal proportion of China Connect in Zhitong Stock on July 10

Statistics on abnormal proportion of Citic Securities Hong Kong Stock Connect on July 9, 2024.

Zhitong FinanceJul 9 20:35 ET

Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).

Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.

Zhitong FinanceJul 8 20:58 ET

Hong Kong stocks are fluctuating. Biomedical stocks have all fallen back due to the policy of innovative drug bullishness. Institutions say that negotiating difficulty has increased in the new environment.

Biomedical stocks fell across the board. As of press time, Remegen (09995) fell 20.18% to HKD 17.24, Tigermed (03347) fell 6.59% to HKD 26.95, Wuxi AppTec (02359) fell 3.95% to HKD 27.95, and Junshi Bio (01877) fell 2.25% to HKD 12.18.

Zhitong FinanceJul 8 03:01 ET

Soochow Securities: "Implementation Plan for Supporting the Development of Innovative Drugs Across the Entire Chain" Approved, and the innovative drugs sector is expected to strengthen.

Soochow Securities released research reports stating that the specific provisions of the "Implementation Plan for Full-chain Support of Innovative Drug Development" are expected to be implemented soon. In addition, the innovative drug sector is currently at a historically relatively low level. In the second half of the year, there will be multiple catalysts such as the ESMO conference, WCLC conference, medical insurance negotiations, and expectations for the innovative drug sector going global, which may lead to a strong performance in the innovative drug sector.

Zhitong FinanceJul 8 02:34 ET